Navigation Links
QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
Date:5/1/2008

EDMONTON, May 1 /PRNewswire/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.

Graeme Macaloney PhD, PEng, Founder, President & CEO of QSV said: "We are extremely pleased and honoured that Pfizer has chosen QSV Biologics from a strong field of contending CMOs as their manufacturing partner for this project. The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV's continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer."

"Pfizer is pleased to engage QSV for the clinical manufacturing of a complex biotechnology product," said Rick Rutter, Ph.D., Vice President of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global Research and Development. "Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer's vision of becoming a top tier biotherapeutic company."

QSV Biologics, Ltd. (http://www.qsvbiologics.com), is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV's facility has a 12 yr track record including an Establishment License for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan "Cu
'/>"/>

SOURCE QSV Biologics, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2011 EMG Laboratory ... the American Association of Neuromuscular & Electrodiagnostic Medicine,s ( ... Status. EMG Laboratory has provided advanced testing of ... Merrimack Valley and Cape Cod since 1997. Currently, it ...
... NEW YORK, Aug. 3, 2011 ... research report is available in its ... and Commercial Outlook 2011-2021 - discovering ... http://www.reportlinker.com/p0578545/Biomarkers-Technological-and-Commercial-Outlook-2011-2021---discovering-the-pharma-and-diagnostics-opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ...
... 2011 Informex , the leading meeting ... today announced the introduction of a new conference, ... the Biopharmaceutical Evolution, to be hosted October 5-6th, ... will cover on-trend topics regarding the future of ...
Cached Biology Technology:EMG Laboratory Attains Prestigious National Accreditation for Clinical Excellence in Neuromuscular Diagnosis 2EMG Laboratory Attains Prestigious National Accreditation for Clinical Excellence in Neuromuscular Diagnosis 3Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 2Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 3Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 4Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 5Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 6Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 7Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 8Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 9Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 10Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 11Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 12Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 13Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 14New Conference Offers Solutions for Success in the Growing Biologics Market 2New Conference Offers Solutions for Success in the Growing Biologics Market 3
(Date:10/19/2014)... the last 30 years contributed only marginally to ... time, according to a new study published in ... access is fundamental to development: it brings improvements ... and health," says IIASA researcher Shonali Pachauri, who ... is widely agreed to be an important goal ...
(Date:10/18/2014)... October 2014 Psychological stress and stress-related psychiatric disorders ... diseases, but the molecular mechanisms underlying this ... contribute to the development of targeted preventive ... these devastating diseases. This work is presented ... in Berlin., Now an international group of ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Researchers find why depression and aging linked to increased disease risk 2Whole-exome sequencing shows potential as diagnostic tool 2
... informal electronic waste salvage site in Ghana,s capital Accra ... pollutants over 50 times higher than risk-free levels. ... field are likewise polluted to varying degrees, all neighbours ... is scavenged for valuable metals - especially copper. Schoolchildren ...
... CHESTNUT HILL, Mass. (October 29, 2011) A major public ... thought leaders for a day-long examination of the contributions of ... university and to society. ,Science in the Liberal Arts ... free public symposium sponsored by BC,s Institute for the Liberal ...
... genome has been decoded. Of all the puzzles it contains, ... the blueprint for various proteins, the building blocks of each ... proteins control cell division in a healthy body, for instance? ... incessantly subdivide and control over proteins gets out of hand? ...
Cached Biology News:High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 2High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 4High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 5Science in the liberal arts university 2Cell cultures from a machine 2
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
... MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide derived ... site of Serine 207 (V-D-S P ... ID: 5608 ...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Biology Products: